We have presented evidence that a tumor-specific ESRRA-C11orf20 fusion transcript is present in a substantial fraction of serous ovarian cancers and that in one of two profiled tumors, Tumor 1, a genomic rearrangement that can account for the fusion transcript is present in a majority of tumor cells. The gene discussed is ESRRA; the disease is ovarian serous adenocarcinoma.